Crisantaspase (Jazz Pharmaceuticals)

天冬酰胺（爵士制药）

Report date: 2026/03/19 20:00:18

Base Information

Drug NameCrisantaspase (Jazz Pharmaceuticals)
Drug Alias NameCrisantaspase (OPi/HPA)Asparaginase Erwinia chrysanthemi (Jazz Pharmaceuticals)Asparaginasecrisantaspase( Jazz Pharmaceuticals)Asparaginase Erwinia chrysanthemi (recombinant)(rywn) +[20] 
ClassificationBiologics > Protein drugs > Enzyme > Non-recombinant enzyme
Mechanisms of ActionAspartate-ammonia ligase inhibitorsAmidohydrolases stimulantsAsparagine inhibitors +[4] 
TargetsAspartate-ammonia ligaseAmidohydrolasesAsparagine +[4] 
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell +[5] 
Global Approved IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2011/11/18
Country/TerritoryCanadaUnited StatesSpain +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHealth Protection Agency
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteJazz Pharmaceuticals IncJazz Pharmaceuticals Plc +[5] 
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-CellLeukemia, B-Cell +[4] 
Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeL01XX02
Related LinksWikipediaDrugBankKEGG